BIOGRAPHICAL SKETCH - PSTP - University of Pittsburgh

BIOGRAPHICAL SKETCH
NAME POSITION TITLE
Michael R. Shurin
Associate Professor of Pathology and Immunology
eRA COMMONS USER NAME
SHURINMR
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
INSTITUTION AND LOCATION
DEGREE
(if applicable)
YEAR(s) FIELD OF STUDY
Moscow State Medical School, Moscow, Russia MD/MS 1984 Medicine, Biochemistry
National Mental Health Research Center, Moscow Postdoctoral 1986 Clinical Biochemistry
Institute for Pharmacology USSR Acad. Med. Sci. PhD 1991 Immunopharmacology
A. Positions and Honors.
1984 - 1986 Postdoctoral Fellow, Laboratory of Clinical Biochemistry, All Union Research Center for Mental
Health, Academy of Medical Science, Moscow, Russia
1986 - 1991 Research Associate, Laboratory of Clinical Immunology, National Mental Health Research
Center, Academy of Medical Science, Moscow, Russia
1991 - 1996 Assistant Professor, Department of Pathology, Div. of Immunopathology, University of
Pittsburgh School of Medicine, Pittsburgh, PA
1996 - 2000 Assistant Professor, Department of Surgery, Div. of Surgical Oncology, University of Pittsburgh
Medical Center and University of Pittsburgh Cancer Institute, Pittsburgh, PA
2000 - Pres Associate Professor, Department of Pathology, Sec. of Laboratory Medicine, University of
Pittsburgh Medical Center, Pittsburgh, PA
2000 - Pres Associate Director, Clinical Immunopathology, UPMC, Pittsburgh, PA
2002 - Pres Associate Professor, Department of Immunology, UPMC, Pittsburgh, PA
•
Honors, Awards and Other Professional Activities:
Member, NIH Site Visit, University of California San Diego, San Diego, CA (1999)
• Grant review committee: NIH NIAID Special Emphasis Panel (SEP) for PO1, 2000, 2001
• External Reviewer, VA Merit Review Boards, 2000, 2001, 2002
• Reviewer, ACGT (Alliance for Cancer Gene Therapy), 2002, 2003, 2004
• Ad Hoc reviewer, OBM-1 Study Section, 2001, 2002, 2003
• Ad Hoc reviewer, TTT Study Section, 2004, 2006
• Chair, ZRG1 ONC-U (1) Study Section, 2005
• Chair, ZHD1 DRG-D (CV) Review group, NIH, 2005
• Ad hoc reviewer, PCTA-1 and 2 study sections, CDMRP/DoD, 2006, 2007
• Ad hoc reviewer, ZRG1 F07-L20 Immunology Fellowship & AREA Study Section, NIH, 2007 (x3), 2008
B. Selected publications (from ~100 total, in chronological order). Do not include publications submitted or in preparation.
• Shurin MR. Dendritic cell presenting tumor antigen. Cancer Immunology Immunother., 43:158-164, 1996.
• Shurin MR, Pandharipande PP, Zorina TD, Haluszczak C, Subbotin VM, Hunter O, Brumfield A, Storkus WJ,
Maraskovsky E, Lotze MT. FLT3-ligand induces the generation of functionally active dendritic cells in mice.
Cellular Immunology, 179:174-184, 1997.
• Esche C, Maliszewski C, Lotze MT, Shurin MR. FLT3 Ligand administration inhibits tumor growth in murine
melanoma and lymphoma. Cancer Res., 58:380-383, 1998.
• Peron J-M, Subbotin VM, Haluszczak C, Maliszewski C, Lotze MT, Shurin MR. FLT3-Ligand Administration
Inhibits Liver Metastases: Role of NK Cells. J.Immunol., 161:6164-6170, 1998.
• Esche C, Lokshin A, Shurin G, Rabinovich H, Gastman BR, Lotze MT, Shurin MR. Tumors’ other immune
targets: Dendritic cells. J.Leukoc. Biol., 336-344,1999.
• Esche C, Gambotto A, Satoh Y, Robbins PD, Watkins SC, Lotze MT, Shurin MR. CD40L inhibits tumorinduced
apoptosis in dendritic cells and tumor growth. Eur. J. Immunol., 29:2148-2155, 1999.
• Pirtskhalaishvili G, Shurin GV, Yurkovetsky ZR, Esche C, Gambotto A, Robbins P, Shurin MR. Transduction
of dendritic cells with Bcl-xL increases their resistance to prostate cancer-induced apoptosis and antitumor
effect in mice. J. Immunol. 165:1956-1964, 2000.
• Pirtskhalaishvili G, Shurin GV, Esche C, Salup RR, Lotze MT, Shurin MR. Protection of human dendritic cells
from prostate cancer-induced apoptosis by IL-12 and IL-15 is mediated by the Bcl-2 family of proteins. British
J. Cancer, 83(4):506-513, 2000.
• Esche C, Cai Q, Hunter O, Peron J-M, Maliszewski C, Wahl M, Lotze MT, Shurin MR. Interleukin-12 and Flt3
ligand differentially promote dendropoiesis in vivo. Eur. J. Immunol., 30(9):2565-2575, 2000.

• Shurin GV, Shurin MR, Bykovskaia S, Shogan J, Lotze MT, Barksdale EM. Neuroblastoma-derived
gangliosides inhibit dendritic cell generation and function. Cancer Res., 61:363-369, 2001.
• Aalamian M, Pirtskhalaishvili G, Esche C, Shurin GV, Huland E, Huland H, Shurin MR. Human prostate
cancer regulates generation and maturation of monocyte-derived dendritic cells. Prostate, 46: 68-75, 2001
• Katsenelson NS, Shurin GV, Bykovskaia SN, Shogan J, Shurin MR. Human Small Cell Lung carcinoma and
carcinoid tumor regulate dendritic cell maturation and function. Modern Pathology, 14(1): 40-45, 2001
• Esche C, Shurin GV, Kirkwood JM, Wang GQ, Rabinowitz H, Pirtskhalaishvili G, Shurin MR. TNF-αpromoted
expression of Bcl-2 and inhibition of mitochondrial cytochrome c release mediate resistance of
mature dendritic cells to melanoma-induced apoptosis. Clinical Cancer Res., 7:974s-979s, 2001
• Pirtskhalaishvili G, Esche C, Shurin GV, Trump D, Shurin MR. TNF-α-mediated protection of dendritic cells
from prostate cancer-induced cell death. Prost. Cancer Prost. Dis., 48: 667-669, 2001
• Shurin MR, Yurkovetsky ZR, Tourkova IL, Balkir L, Shurin GV. Inhibition of CD40 expression and CD40mediated
dendritic cell function by tumor-derived IL-10. Intl. J. Cancer. 101:61-68, 2002.
• Satoh Y, Esche C, Gambotto A, Shurin GV, Yurkovetsky ZR, Robbins PD, Watkins SC, Todo S, Lotze MT,
Herberman R, Shurin MR. Local Administration of IL-12-transfected Dendritic Cells Induces Antitumor
Immune Responses to Colon Adenocarcinoma in the Liver in Mice. J. Exp. Therap.Oncol. 2:337-349, 2002.
• Tourkova IL, Yurkovetsky ZR, Gambotto A, Makarenkova V, Perez L, Balkir L, Robbins PD, Shurin MR,
Shurin GV. Increased Function and Survival of IL-15-transduced Human Dendritic Cells are Mediated by Upregulation
of IL-15Rα and Bcl-2. J Leukoc Biol., 72:1037-1045, 2002.
• Tourkova IL, Yamabe K, Chatta G, Shurin GV, Shurin MR. NK cells mediate Flt3 ligand-induced protection of
dendritic cell precursors in vivo from inhibition by prostate carcinoma in the bone marrow metastasis model.
J. Immunotherapy, 26:468-472, 2003.
• Aalamian M, Tourkova IL, Chatta G, Lilja H, Huland E, Huland H, Shurin GV, Shurin MR Inhibition of
Dendropoiesis by Tumor-derived and Purified PSA. J. Urology, 170:2026-2030, 2003.
• Makarenkova VP, Shurin GV, Tourkova IL, Balkir L, Pirtskhalaishvili G, Gerein V, Siegfried JM, Shurin MR.
Lung cancer-derived bombesin-like peptides down-regulate the generation and function of human dendritic
cells. J. Neuroimmunology. 145:55-67, 2003.
• Tourkova IL, Yamabe K, Foster B, Chatta G, Shurin GV, Shurin MR. Murine prostate cancer both in vitro and
in vivo inhibits dendritic cell generation from bone marrow precursors. Prostate, 59:203-213, 2004.
• Balkir L, Shurin GV, Robbins PD, Chatta G, Shurin MR. Comparative analysis of dendritic cells transduced
with different anti-apoptotic molecules: Sensitivity to tumor-induced apoptosis. J Gene Med. 6:537-544, 2004.
• Shurin GV, Chatta GS, Tourkova IL, Zorina TD, Esche C, Shurin M.R. Regulation of dendritic cell expansion
in aged athymic nude mice by FLT3 ligand. Exper. Gerontol., 39:339-348, 2004.
• Guruli G, Pflug BR, Pecher S, Makarenkova V, Shurin MR, Nelson JB. Function and survival dendritic cells
depend on endothelin-1 and endothelin receptors autocrine loops. Blood, 104:2107-2115, 2004.
• Whiteside TL, Stanson J, Shurin MR, Ferrone S. Antigen-Processing Machinery in Human Dendritic Cells:
Up-Regulation by Maturation and Down-Regulation by Tumor Cells. J. Immunol. 173:1526–1534, 2004.
• Perez L, Collins B, Shurin MR, Shurin GV. Comparative analysis of CD1a+, S100+, CD11c+, and CD83+
human dendritic cells in normal, premalignant and tumor tissues. Histol. Histopath. 20: 1165-1172, 2005.
• Shurin GV, Tourkova IL, Chatta GS, Schmidt G, Wei S, Djue J, Shurin MR. Small Rho GTPases Regulate
Antigen Presentation in Dendritic Cells. J. Immunol. 174:3394-3400, 2005.
• Shurin GV, Ferris R, Tourkova IL, Perez L, Lokshin A, Chatta GS, Shurin MR. Loss of new chemokine
CXCL14 in tumor tissue is associated with low Infiltration by dendritic cells, while restoration of human
CXCL14 expression in tumor cells causes attraction of dendritic cells both in vitro and in vivo. J. Immunol.
174:5490-5498, 2005.
• Tourkova IL, Shurin GV, Chatta GS, Perez L, Finke J, Whiteside TL, Ferrone S, Shurin MR. Restoration by
IL-15 of MHC class I antigen processing machinery in human dendritic cells inhibited by tumor-derived
gangliosides. J. Immunol. 175: 3045-3052, 2005.
• Yurkovetsky ZR, Shurin GV, Barry DA, Schuh AC, Shurin MR, Robbins PD. Comparative Analysis of
Antitumor Activity of CD40L, RANKL, and 4-1BBL in vivo Following Intratumoral Administration of Viral
Vectors or Transduced Dendritic Cells. J Gene Medicine, 8(2):129-37, 2006.
• Shurin MR, Shurin GV, Lokshin A, Yurkovetsky ZR, Gutkin DW, Chatta GS, Zhong H, Han B, Ferris RL.
Intratumoral cytokines/chemokines.growth factors and tumor infiltrating dendritic cells: Friends or enemies?
Cancer Metastasis Reviews, 25(3): 333-356, 2006.
• Tourkova IL, Shurin GV, Wei S, Shurin MR. Small Rho GTPases mediate tumor-induced inhibition of
endocytic activity of dendritic cells. J. Immunol. 178(12): 7787-7793, 2007.
• Shurin M, Smolkin Y. Immune-mediated diseases: where do we stand? Adv.Exp.Med.Biol. 601:3-12, 2007.
• Zhong H, Han B, Tourkova IL, Lokshin A, Rosenbloom A, Shurin MR, Shurin GV. Low-Dose Paclitaxel Prior
to Intratumoral Dendritic Cell Vaccine Modulates Intratumoral Cytokine Network and Lung Cancer Growth.
Clin. Cancer Res. 13(18): 5455-5462, 2007.
• Shurin MR. Immune-mediated diseases: from theory to therapy. IDrugs 10(11): 762-764, 2007.

C. Research Support. List selected ongoing or completed (during the last three years) research projects (federal and
non-federal support). Begin with the projects that are most relevant to the research proposed in this application. Briefly
indicate the overall goals of the projects and responsibilities of principal investigator identified above.
Shurin, Michael R.
ONGOING
2RO1 CA84270 Shurin (Principal Investigator) 02/01/04 – 01/30/09
30%
NIH/NCI
Control of Dendritic Cell Generation and Function by Tumor
The aims of this grant is to evaluate the regulation of dendritic cell
maturation by tumor-derived factors and examine the role of small
Rho GTPaeases in these mechanisms in the murine system.
Shurin, Michael R.
ONGOING
P20 Herberman (Principal Investigator) 5P20CA103730
NIH Shurin (Co-investigator)
Cancer and Aging Center Planning Grant
Shurin, Michael R.
ONGOING
DOD (Idea Award) PC050252 Shurin (Principal Investigator)
Epigenetic regulation of chemokine expression in Prostate Cancer
The major focus of this project is to determine the mechanisms
responsible for down-regulating expression of chemokines in
prostate cancer cell lines and primary tumors
10/01/03 – 09/30/08
12/01/05 - 11/30/08
Shurin, Michael R.
COMPLETED
RO1 CA84270 Shurin (Principal Investigator)
NIH/NCI
Control of Dendritic Cell Generation and Function by Tumor
The aims of this grant was to evaluate regulation of dendritic cell maturation by
melanoma- and neuroblastoma-derived gangliosides and other factors and
examine immunotherapeutic approaches to protect dendropoiesis
Shurin, Michael R.
COMPLETED
RO1 CA80126 Shurin (Principal Investigator)
NIH/NCI
Tumor Associated Dendritic Cells
The major goals were to determine the trafficking and behavior of dendritic cells in
the tumor tissue and evaluate the role of FLT3 ligand in DC regulation.
Shurin, Michael R.
COMPLETED
DAM017-00-1-0099 Shurin (Principal Investigator)
DOD (Idea Award)
Immune Gene Therapeutic Correction of Disordered Dendritic Cells in Prostate
Cancer
The major focus of this project was the development of new adenovirus vectors for
targeting murine dendritic cells. In addition, the project focuses on evaluation of
means to generate DC in vitro and determine ways to express genes in these cells.
Shurin, Michael R.
COMPLETED
5%
30%
12/01/99 – 1/30/03
12/01/98 – 1/30/03
02/01/00 - 03/31/03

PO-99013 Shurin (Principal Investigator)
The Pittsburgh Foundation for Medical Research (Clinical Trial Support Program)
New Approach for Prostate Cancer Therapy: Dendritic Cell Protected from Tumorinduced
Death
The aim of this project is to prepare a randomized phase I/II clinical trial to evaluate
the efficacy of immunization of prostate cancer patients using autologous dendritic
cells protected from apoptosis.
Shurin, Michael R.
COMPLETED
UPCI Lung Cancer SPORE Project Shurin (Principal Investigator)
Development Research Pilot Project Grant
Molecular targets for reversal of lung cancer-mediated immunosuppression
The aim of this study is to evaluate human lung cancer-derived factors responsible
for alterations of dendritic cell ability to induce efficient antitumor immune
responses.
Shurin, Michael R.
COMPLETED
Prostate and Urologic Cancer Center Pilot Project Support
Shurin (Principal Investigator)
University of Pittsburgh Cancer Institute
Effective Protection of Human Dendritic Cells from Prostate Cancer Induced Cell
Death
The major goals of this pilot project was to collect preliminary data evaluating in
vitro effects of human cytokines on the survival of cultured dendritic cells and
determine the optimal conditions for cytokine-induced protection of dendritic cells
from prostate cancer-induced apoptosis.
Shurin, Michael R.
COMPLETED
Competitive Medical Research Fund Shurin (Principal Investigator)
University of Pittsburgh Medical Center
Induction of an Antitumor Response Using Dendritic Cells: Murine Models of
Combination Therapy with IL-12
This study focused on the combination of dendritic cells and IL-12 immunotherapy
in murine tumor systems and mechanisms regulating migration of dendritic cells to
the site of the tumor.
Shurin, Michael R.
COMPLETED
George Heckman Award Shurin (Principal Investigator)
American Cancer Society and UPCI
FLT3 Ligand as a Novel Cytokine for Anticancer Immunotherapy
The objective of this project was to determine the antitumor efficacy of a new
dendritic cell growth factor FLT3 ligand using murine tumor models.
07/01/99 –
06/30/02
02/01/02–
12/31/03
01/01/99 –
12/31/99
07/01/97 –
06/30/98
10/01/96 –
09/30/97